Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT04438096
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- CVI Pharmaceuticals
- Registry
-
NCT04438096
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04438096. Randomized; quadruple masking; primary purpose treatment. Start 2020-07-15 (anticipated); primary completion 2021-12-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia
- Condition
- Hyperlipidemia
- Intervention (Drug)
- 100 mg
- Intervention (Drug)
- 200 mg
- Intervention (Drug)
- 300 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- CVI Pharmaceuticals
Record details
- Record id
cardio:ct-nct04438096- Content hash
8e8f35a9dd0466d368a54a4d56d7df0e871c0657364c4253fb3d5425ed6fe0ba